Address the complexity of protein characterization

Since the FDA approved the first monoclonal based therapy in 1985, mAbs have had significant clinical success and have been used to provide effective treatment for a range of diseases. During development and quality control, you may use a range of analytical technologies to characterize biotherapeutic drugs in terms of their structural integrity and activity. In this presentation, I share some examples on the use of Biacore™ surface plasmon resonance (SPR) systems for active concentration measurement, target binding, and describe how you can use these assays for assessment of drug potency (EC50) and stability.

Download white paper to learn more: https://cytiva.link/5qolo